ponalrestat has been researched along with Diabetic Neuropathies in 23 studies
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ponalrestat was clinically well tolerated and had no significant effect on glycaemic control." | 2.67 | A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. ( Ellis, SH; Hardman, M; Honigsberger, L; Krentz, AJ; Nattrass, M, 1992) |
| "Ponalrestat treatment completely prevented the characteristic nerve conduction slowing and structural abnormalities of the node of Ranvier for 4 mo despite only partial preservation of axonal integrity." | 1.28 | Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat. ( Chakrabarti, S; Greene, DA; Prashar, A; Sima, AA; Zhang, WX, 1990) |
| "Galactose feeding was associated with a 21." | 1.28 | Coexistence of nerve conduction deficit with increased Na(+)-K(+)-ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy. ( Biswas, S; Calcutt, NA; Tomlinson, DR, 1990) |
| "Myo-inositol treatment did not affect nerve levels." | 1.28 | The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. ( Cameron, NE; Cotter, MA; Robertson, S, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 17 (73.91) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Florkowski, CM | 2 |
| Kamijo, M | 2 |
| Cherian, PV | 1 |
| Sima, AA | 3 |
| Valensi, P | 1 |
| Attali, JR | 1 |
| Gagant, S | 1 |
| Krans, HM | 1 |
| Boland, OM | 1 |
| Blackwell, CC | 1 |
| Clarke, BF | 1 |
| Ewing, DJ | 1 |
| Mizisin, AP | 1 |
| Powell, HC | 1 |
| Faes, TJ | 1 |
| Yff, GA | 1 |
| DeWeerdt, O | 1 |
| Lanting, P | 1 |
| Heimans, JJ | 1 |
| Bertelsmann, FW | 1 |
| Pfeifer, MA | 1 |
| Schumer, MP | 1 |
| Gelber, DA | 1 |
| Yasuda, H | 1 |
| Sonobe, M | 1 |
| Hisanaga, T | 1 |
| Kawabata, T | 1 |
| Maeda, K | 1 |
| Kikkawa, R | 1 |
| Shigeta, Y | 1 |
| Cameron, NE | 2 |
| Cotter, MA | 2 |
| Krentz, AJ | 1 |
| Honigsberger, L | 1 |
| Ellis, SH | 1 |
| Hardman, M | 1 |
| Nattrass, M | 1 |
| Ziegler, D | 1 |
| Mayer, P | 1 |
| Rathmann, W | 1 |
| Gries, FA | 1 |
| Yagihashi, S | 1 |
| Rowe, BR | 1 |
| Nightingale, S | 1 |
| Harvey, TC | 1 |
| Barnett, AH | 1 |
| Zhang, WX | 2 |
| Chakrabarti, S | 2 |
| Greene, DA | 2 |
| Prashar, A | 1 |
| Calcutt, NA | 1 |
| Tomlinson, DR | 1 |
| Biswas, S | 1 |
| Dahlin, LB | 1 |
| Archer, DR | 1 |
| McLean, WG | 1 |
| Robertson, S | 1 |
| Umeda, F | 1 |
| Noda, K | 1 |
| Hashimoto, T | 1 |
| Yamashita, T | 1 |
| Nawata, H | 1 |
| Sundkvist, G | 1 |
| Lilja, B | 1 |
| Rosén, I | 1 |
| Agardh, CD | 1 |
| Hotta, N | 1 |
| Sakamoto, N | 1 |
| Kador, PF | 1 |
| Kinoshita, JH | 1 |
| Sharpless, NE | 1 |
4 reviews available for ponalrestat and Diabetic Neuropathies
| Article | Year |
|---|---|
Recent clinical experience with aldose reductase inhibitors.
Topics: Aldehyde Reductase; Biopsy; Diabetic Neuropathies; Double-Blind Method; Humans; Imidazoles; Imidazol | 1993 |
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Topics: Aldehyde Reductase; Autonomic Nervous System; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Imid | 1997 |
[Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies | 1987 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; | 1985 |
10 trials available for ponalrestat and Diabetic Neuropathies
| Article | Year |
|---|---|
The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
Topics: Aldehyde Reductase; Diabetes Complications; Diabetic Neuropathies; Double-Blind Method; Humans; Phth | 1993 |
Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
Topics: Aldehyde Reductase; Analysis of Variance; Blood Glucose; Blood Pressure; Diabetic Neuropathies; Doub | 1993 |
Recent clinical experience with aldose reductase inhibitors.
Topics: Aldehyde Reductase; Biopsy; Diabetic Neuropathies; Double-Blind Method; Humans; Imidazoles; Imidazol | 1993 |
Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Topics: Aldehyde Reductase; Analysis of Variance; Autonomic Nervous System; Blood Pressure; Diabetes Mellitu | 1993 |
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
Topics: Aldehyde Reductase; Autonomic Nervous System Diseases; Diabetic Neuropathies; Double-Blind Method; F | 1993 |
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Topics: Aldehyde Reductase; Autonomic Nervous System; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Imid | 1997 |
A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
Topics: Action Potentials; Adult; Aldehyde Reductase; Analysis of Variance; Blood Pressure; Diabetic Neuropa | 1992 |
One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dou | 1991 |
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
Topics: Aldehyde Reductase; Diabetic Neuropathies; Humans; Median Nerve; Middle Aged; Neurons, Afferent; Pht | 1991 |
Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Topics: Adult; Aldehyde Reductase; Autonomic Nervous System Diseases; Clinical Trials as Topic; Diabetic Neu | 1987 |
11 other studies available for ponalrestat and Diabetic Neuropathies
| Article | Year |
|---|---|
The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.
Topics: Aldehyde Reductase; Animals; Atrophy; Axons; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Diabe | 1993 |
Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication.
Topics: Aldehyde Reductase; Animals; Body Water; Diabetic Neuropathies; Electrolytes; Female; Galactose; Pht | 1993 |
A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
Topics: Aldehyde Reductase; Alprostadil; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Hy | 1992 |
Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Fructose; Hypoglycem | 1992 |
[Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy].
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Peripheral Nerv | 1991 |
Diabetic autonomic neuropathy in BB rats and effect of ARI treatment on heart-rate variability and vagus nerve structure.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Diabetic Neuropathies; Glycated Hemoglobin; | 1990 |
Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
Topics: Aldehyde Reductase; Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropa | 1990 |
Coexistence of nerve conduction deficit with increased Na(+)-K(+)-ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Diabetic Neuropathies; Diet; Female; Galactose; Mice; Mice, Inbred Stra | 1990 |
Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.
Topics: Aldehyde Reductase; Animals; Axonal Transport; Diabetes Mellitus, Experimental; Diabetic Neuropathie | 1987 |
The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Inositol; Kinet | 1989 |
Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Erythrocyte Membrane; Female; | 1989 |